Share

September 2018; 5 (5) ArticleOpen Access

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS

Felix Luessi, Sinah Engel, Annette Spreer, Stefan Bittner, Frauke Zipp
First published July 13, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000481
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
29605

Share

Article Information

vol. 5 no. 5 e481
DOI: 
https://doi.org/10.1212/NXI.0000000000000481
PubMed: 
30027106
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 16, 2018
  • Accepted in final form May 31, 2018
  • First Published July 13, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Felix Luessi, MD*,
    2. Sinah Engel*,
    3. Annette Spreer, MD,
    4. Stefan Bittner, MD and
    5. Frauke Zipp, MD
  1. Felix Luessi, MD*,
    2. Scientific Advisory Boards:

    1. advisory board member for Roche Pharma

    Gifts:

    1. travel grants from Teva Pharma and Merck Serono

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Sinah Engel*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Annette Spreer, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Deutsche Gesellschaft f?r Liquoranalytik und Neurochemie, funding for travel to speak at conferences and Workshops (2) Institut Virion/Serion GmbH, W?rzburg, funding for travel to speak at educational workshop

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. BMG /RKI, #1369-487, Lead investigator,2015-2017

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Stefan Bittner, MD and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. S.B. has received honoraria for travel or speaker honoria from Biogen Idec, Merck Serono, Novartis, Roche and Sanofi- Genzyme.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Frauke Zipp, MD
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Teva, research grant and travel compensation (2) Novartis, research grant, consultation funds and travel compensation (3) Merck Serono, research grant and travel compensation (4) Bayer, research grant and travel compensation (5) Biogen Idec Germany, consultation funds and travel funds (6) Ono, consultation funds and travel funds (7) Genzyme, consultation funds and travel funds (8) Sanofi-Aventis, consultation funds and travel funds (9) Octapharma, consultation funds and travel funds

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Teva (2) Merck Serono (3) Novartis (4) Bayer Healthcare (5) Biogen Idec Germany (6) Ono (7) Genzyme (8) Sanofi-Aventis (9) Octapharma

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) DFG CRC128, Spokesperson/PI, 2012-2020 (2) DFG CRC1080, PI, 2013-2020 (3) BMBF KKNMS, Executive Board/PI, 2013-2019 (4) PCORI PRAG-MS, Director Subcontracted Organization, 2017-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Progressive MS Alliance - BRAVEinMS

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology and Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Germany.
  1. Correspondence
    Dr. Luessi luessi{at}uni-mainz.de
View Full Text

Article usage

Article usage: July 2018 to May 2023

AbstractFullPdfSource
Jul 2018138156Highwire
Aug 2018136630Highwire
Aug 20183693114pmc
Sep 2018026863Highwire
Oct 2018022735Highwire
Nov 201809814Highwire
Dec 2018010160Highwire
Jan 20192698Highwire
Feb 2019106015Highwire
Mar 201957318Highwire
Apr 2019798034Highwire
May 2019212047583Highwire
Jun 2019103335501Highwire
Jul 201972002573Highwire
Aug 2019434731123Highwire
Sep 201971971865Highwire
Oct 201991787879Highwire
Nov 2019181314299Highwire
Dec 2019642912688Highwire
Jan 2020129422240Highwire
Feb 2020533151859Highwire
Mar 20201053774673Highwire
Apr 2020619181393Highwire
May 2020629232016Highwire
Jun 2020326882087Highwire
Jul 2020318266Highwire
Aug 20201584521Highwire
Sep 20204172136Highwire
Oct 20203634611Highwire
Nov 2020311721115Highwire
Dec 20205354305Highwire
Jan 20216309Highwire
Feb 202104517Highwire
Mar 202124218Highwire
Apr 20214110167Highwire
May 202134517Highwire
Jun 202175024Highwire
Jul 202144012Highwire
Aug 20216519Highwire
Sep 202113621Highwire
Oct 202144131Highwire
Nov 202124126Highwire
Dec 2021123612Highwire
Jan 2022203939Highwire
Feb 2022153829Highwire
Mar 202264717Highwire
Apr 202211611Highwire
May 202262620Highwire
Jun 20223226Highwire
Jul 202256619Highwire
Aug 202283312Highwire
Sep 2022225016Highwire
Oct 202284218Highwire
Nov 2022167021Highwire
Dec 2022142912Highwire
Jan 202313326Highwire
Feb 202313288Highwire
Mar 202321426Highwire
Apr 202316118Highwire
May 2023101414Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles